| Followers | 102 |
| Posts | 12709 |
| Boards Moderated | 0 |
| Alias Born | 10/29/2012 |
Thursday, December 31, 2020 2:21:07 PM
I wrote an email to Sian Capital about hiring an independent company to go over $OPK and this was the response :
If you read our materials, you would know we have hired several far superior to Huron consulting firms as well as spoken to many acquirers. More importantly, we have run your name thru analytics, and have made clear in our materials, which you say you read, if you visit our website, please forward us your correspondence with the Board of Directors you support Sian, we have templates on Rayadee section to simply copy and paste your congressman, can email the analysts on the stock to answer the questions and we spoke to them Friday and have received almost no retail holder emails - just the institutions we put in the stock. Further social media and contacting news is helpful. Pls forward your doing this to this address. Doing this, in large numbers, is how the Company is pressured if, say, the news picks it up or the House Oversight Committee or your congressman writs a letter. Further, given your money is in Opko: why wouldn't you do this as you are economically motivated to do so. We have stated numerous times we dialogue with our investors and supporters. If you would like to invest in Sian, whose returns are of course far superior, you can contact your Goldman Sachs Private Banker. But or analytics team just ran a scan and shows no such correspondence from you. We are happy to dialogue, but dialogue with our investors and our supporters as displayed by actions above. If you invested in Opko, talking with them and emailing their Board, as we stated is more useful. And of course, you must know this as an investor, but you will be emailing the Board directly. They trick many retail investors, as I'm sure as you know - make sure they don't shoo you away to their external Ir firm LHA who they pay $8 millionn+ a year on to avoid shareholders. They have also hired two high priced PR firms to fight Sian (at 2mm/month plus expenses). Pls forward that correspondence to this email and we are happy to discuss questions you have. but if you invested your money in opko - you should be speaking not to LHA, not to Sian, but to Opko. Thanks again.
If you read our materials, you would know we have hired several far superior to Huron consulting firms as well as spoken to many acquirers. More importantly, we have run your name thru analytics, and have made clear in our materials, which you say you read, if you visit our website, please forward us your correspondence with the Board of Directors you support Sian, we have templates on Rayadee section to simply copy and paste your congressman, can email the analysts on the stock to answer the questions and we spoke to them Friday and have received almost no retail holder emails - just the institutions we put in the stock. Further social media and contacting news is helpful. Pls forward your doing this to this address. Doing this, in large numbers, is how the Company is pressured if, say, the news picks it up or the House Oversight Committee or your congressman writs a letter. Further, given your money is in Opko: why wouldn't you do this as you are economically motivated to do so. We have stated numerous times we dialogue with our investors and supporters. If you would like to invest in Sian, whose returns are of course far superior, you can contact your Goldman Sachs Private Banker. But or analytics team just ran a scan and shows no such correspondence from you. We are happy to dialogue, but dialogue with our investors and our supporters as displayed by actions above. If you invested in Opko, talking with them and emailing their Board, as we stated is more useful. And of course, you must know this as an investor, but you will be emailing the Board directly. They trick many retail investors, as I'm sure as you know - make sure they don't shoo you away to their external Ir firm LHA who they pay $8 millionn+ a year on to avoid shareholders. They have also hired two high priced PR firms to fight Sian (at 2mm/month plus expenses). Pls forward that correspondence to this email and we are happy to discuss questions you have. but if you invested your money in opko - you should be speaking not to LHA, not to Sian, but to Opko. Thanks again.
Recent OPK News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/15/2026 08:38:03 PM
- OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:04:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:01:43 PM
- OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform • GlobeNewswire Inc. • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:06:14 PM
- OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results • GlobeNewswire Inc. • 04/28/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
